Industry Newsoncologyrasclinical trialserasca
Erasca Stock Surges After Early Clinical Responses
3.8
Erasca Inc. rallied for a second day Thursday, jumping 13.04% to close at $15.26 as investors positioned ahead of initial clinical data for its pan‑RAS degrader ERAS-0015 in the US and China. In January, the company reported two confirmed partial responses and one unconfirmed response during dose escalation, plus additional unconfirmed responses at 8 mg and consistent pharmacokinetics.
Key Points
- 1Reports show two confirmed and one unconfirmed partial responses for ERAS-0015 in dose-escalation study
- 2Investors bid shares up 13.04% amid 310% year-to-date rally and trial anticipation
- 3Practitioners should monitor forthcoming US and China trial data for clinical and market impact
Scoring Rationale
Moderate market-moving clinical update with clear investor impact, but limited novelty and reliance on early single-source data.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
